Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | TPO | P07202 | 1/20 | 0.39 |
| ▸ | EPX | P11678 | 1/20 | 0.39 |
| ▸ | LPO | P22079 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190759 | 0.81 | GCK (0.54) | GCKPDPK1KMT2A | |
| SCHEMBL12410844 | 0.76 | MPO (0.47) | MPOTPOEPXLPOPDPK1 | |
| SCHEMBL31210714 | 0.76 | PDPK1 (0.44) | MPOTPOEPXLPOPDPK1 | |
| SCHEMBL2657460 | 0.70 | ADORA2A (0.42) | GCK | |
| SCHEMBL211570 | 0.69 | — | — | |
| SCHEMBL25261303 | 0.69 | HTR2C (0.37) | — | |
| SCHEMBL30501182 | 0.69 | HTR2C (0.37) | — | |
| SCHEMBL29377685 | 0.69 | POLB (0.47) | FGFR1POLBL3MBTL1 | |
| SCHEMBL4790717 | 0.69 | POLB (0.47) | FGFR1POLBL3MBTL1 | |
| SCHEMBL30606160 | 0.68 | ALOX5AP (0.38) | PDPK1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431713-B2 | 2-aminopyridine derivatives as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2010-04-22 | — | — | US | disclosed |
| WO-2008091770-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099713-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | MPO 2691/4885TPO 1481/4885EPX 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.